Skip to main content
Johnson & JohnsonFunding

J&J Secures $750 Million in Blackstone R&D Funding, Pending Ollin Closing

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson secured $750 million in R&D funding from Blackstone Life Sciences for Phase 3 development of OLN324, contingent on closing its Ollin acquisition.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Blackstone announced on November 16, 2026 that funds managed by Blackstone Life Sciences will provide $750 million to Johnson & Johnson ( JNJ ) for Phase 3 development of OLN324, an investigational therapy for serious retinal vascular diseases. The agreement is contingent on Johnson & Johnson completing its proposed acquisition of Ollin Biosciences. The money will be paid over multiple years and fully fund that development, according to Johnson & Johnson's companion announcement. The clinical program covers wet age-related macular degeneration and diabetic macular edema. In return, Blackstone will be eligible for certain regulatory and sales milestone payments and single-digit royalties. The arrangement separates the company acquisition from late-stage research financing. Johnson & Johnson would add OLN324 to its pipeline through the Ollin purchase, while Blackstone would finance the trials in exchange for milestone payments and royalties. Blackstone would therefore be a funding partner in the acquired drug's development rather than a buyer of Ollin. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the agreement expands Blackstone's relationship with Johnson & Johnson and demonstrates its ability to provide capital at scale for pharmaceutical development. Johnson & Johnson has entered into a definitive agreement to acquire Ollin, a clinical-stage...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Funding

What this signalsNew funding often brings new budget and vendor reviews.

Takes effect
Nov 16, 2026

More funding signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
receives_financing

Use this data

Get every funding signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns funding signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/8e3f5a6a-75b6-f6c9-9a51-3381fb284e9a returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "8e3f5a6a-75b6-f6c9-9a51-3381fb284e9a",
  "signal_type": "news",
  "signal_subtype": "receives_financing",
  "detected_at": "2026-11-16T14:42:02+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.securities.io/j-and-j-secures-750-million-in-blackstone-r-and-d-funding-pending-ollin-closing/",
    "title": "J&J Secures $750 Million in Blackstone R&D Funding, Pending Ollin Closing - Securities.io",
    "excerpt": "Blackstone announced on November 16, 2026 that funds managed by Blackstone Life Sciences will provide $750 million to Johnson & Johnson ( JNJ ) for Phase 3 development of OLN324, an investigational therapy for serious retinal vascular diseases. The agreement is contingent on Johnson & Johnson completing its proposed acquisition of Ollin Biosciences. The money will be paid over multiple years and fully fund that development, according to Johnson & Johnson’s companion announcement . The clinical program covers wet age-related macular degeneration and diabetic macular edema. In return, Blackstone will be eligible for certain regulatory and sales milestone payments and single-digit royalties. The arrangement separates the company acquisition from late-stage research financing. Johnson & Johnson would add OLN324 to its pipeline through the Ollin purchase, while Blackstone would finance the trials in exchange for milestone payments and royalties. Blackstone would therefore be a funding partner in the acquired drug’s development rather than a buyer of Ollin. Nicholas Galakatos, Global Head of Blackstone Life Sciences, said the agreement expands Blackstone’s relationship with Johnson & Johnson and demonstrates its ability to provide capital at scale for pharmaceutical development. Johnson & Johnson has entered into a definitive agreement to acquire Ollin, a clinical-stage...",
    "summary": "Johnson & Johnson secured $750 million in R&D funding from Blackstone Life Sciences for Phase 3 development of OLN324, contingent on closing its Ollin acquisition.",
    "planning": true,
    "image_url": "https://www.securities.io/wp-content/uploads/2026/11/blackstone-to-fund-750-million-of-johnson-johnson-eye-drug-trials.jpg",
    "confidence": 0.95,
    "published_at": "2026-11-16T14:42:02Z",
    "effective_date": "2026-11-16",
    "article_sentence": "Blackstone announced on November 16, 2026 that funds managed by Blackstone Life Sciences will provide $750 million to Johnson & Johnson ( JNJ ) for Phase 3 development of OLN324, an investigational therapy for serious retinal vascular diseases.",
    "related_company_name": "Blackstone",
    "related_company_domain": "blackstone.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.